PeriVision secures CHF 2.4 million to expand VR eye testing platform

PeriVision has raised CHF 2.4 million in seed funding to accelerate the development of its AI-driven VR eye testing platform, expanding diagnostics for glaucoma and retinal diseases.

PeriVision, a spin-off from the University of Bern and Inselspital, has announced a CHF 2.4 million seed round to advance its ambitious growth roadmap. The funding will support the development of new retina disease tests, advanced AI insights, and system integrations, expanding the scope of its VR-based VisionOne platform for use in clinics, optometry practices, and biopharma research.

The financing round was led by ARYA VC with participation from DART Ventures, Zühlke Ventures, MEDKAP, SICTIC, Is Bank’s AI Factory, Venture Kick, InaTec, Juchum Foundation, CADFEM and OOMNIUM. This mix of venture funds, family offices, and business angel networks adds both capital and strategic expertise to guide the company’s next phase.

Glaucoma and other eye diseases affect millions worldwide, with late diagnosis often leading to irreversible blindness. Traditional vision testing methods remain time-intensive and resource-heavy, limiting access. PeriVision’s VisionOne platform, already certified in the EU, US, and UK, leverages commercial VR headsets and proprietary AI algorithms to deliver faster, more reliable, and patient-friendly visual field tests. The solution aims to improve outcomes for over 100 million glaucoma patients globally while reducing the burden on healthcare systems.

A new standard in vision diagnostics

The company has already gained traction with early commercial adoption and distribution agreements in multiple European markets. Supported by earlier recognition, including the CE marking of VisionOne, a CHF 300,000 FIT loan, and participation in programs such as Venture Leaders Medtech and the Biopôle Vanguard Accelerator,  PeriVision has emerged as a leading healthtech innovator in Western Switzerland.

As part of the round, Arijana Walcott, Managing Director at DART Ventures, joins the board, while Sanem Tatlidil Özal of ARYA VC takes on an observer role. Both bring international expertise in scaling technology and healthcare ventures.

“With this funding, we are positioned to broaden our clinical offering and scale globally,” said Patrick Kessel, CEO of PeriVision. “Our mission is to redefine how vision diagnostics are delivered, making them faster, smarter, and more accessible worldwide.”